GNPX - Genprex Inc logo

GNPX

Genprex Inc

Rev โ€”top 1%5Y
Hold

Genprex, Inc. develops gene therapies targeting cancer and diabetes. Its lead candidate, Reqorsa, is in clinical trials for non-small cell and small cell lung cancer, while its diabetes therapy aims to deliver genes to rejuvenate insulin-producing cells in the pancreas.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth23.13%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth9.55%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-31.17%
Net Trend43%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Genprex Inc fundamental performance

Across Genprex Inc's full reported history, from 2018 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 12M to -$ 16M. Revenue increased in 0% of the years measured; net income in 43%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.73โ€”
1 Year2025-08-12
$ 258.50-98.17%
5 Years2021-08-12
$ 127.6K-100.00%
All Time2018-03-29
$ 206.8K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 16M$ 7M
2024$ 0.00-$ 21M$ 1M
2023$ 0.00-$ 30M$ 6M
2022$ 0.00-$ 23M$ 20M
2021$ 0.00-$ 20M$ 38M
2020$ 0.00-$ 17M$ 27M
2019$ 0.00-$ 10M$ 2M
IPO2018$ 0.00-$ 12M$ 8M

Explore beyond GNPX

You're looking at Genprex Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies